Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Androgen Deprivation Therapy

Androgen Deprivation Therapy

6

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Androgen Deprivation Therapy is an early-stage landscape with 6 programs across 3 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

25/100

Attrition Rate

43/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 1

No programs

Phase 25

Intense Androgen Deprivation Therapy

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Rezvilutamide

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Relugolix

Sumitomo Pharma America, Inc.

Leuprolide Acetate

Eastern Cooperative Oncology Group

Darolutamide

Bayer

Phase 31

Imab

European Organisation for Research and Treatment of Cancer - EORTC

Approved

No programs

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 100% of 6 pipeline programs.

Analysis

Trial Status

14

clinical trials

Terminated4 · 29%

Recruiting4 · 29%

Completed2 · 14%

Withdrawn2 · 14%

Unknown status1 · 7%

Active, not recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT05974774·1,600 enrolled

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Recruiting·PPeking University First Hospital·Phase 2·NCT06348264·37 enrolled

Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06992232·144 enrolled

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy: POWER Trial

Recruiting·DDana-Farber Cancer Institute·Preclinical·NCT05327465·62 enrolled

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Active, not recruiting·—·Phase 2·NCT06463457·33 enrolled

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

Completed·UUrology Clinics of North Texas·Phase 1·NCT07069465·10 enrolled

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Completed·MMedical College of Wisconsin·N/A·NCT02366494·42 enrolled

Androgen Deprivation Therapy Study

Terminated·National Institute on Aging (NIA)·N/A·NCT00743327·1 enrolled

Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose

Terminated·NNorwegian School of Sport Sciences·N/A·NCT03440879·23 enrolled

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Terminated·—·Phase 3·NCT03777982·12 enrolled

Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy

Terminated·UUniversity of Colorado, Denver·Approved·NCT05700903·10 enrolled

Study of Dasatinib, Androgen Deprivation Therapy and Radiation

Withdrawn·—·Phase 1·NCT01826838

Black Cohosh for Host Flashes Due to Androgen Deprivation Therapy

Withdrawn·MMidwestern Regional Medical Center·Phase 2·NCT02952742

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Unknown status·FFudan University·Phase 2·NCT02742675·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)